AMPH - CIK 0001297184
Amphastar Pharmaceuticals, Inc. (AMPH) reported net income of $98.09M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $98.09M | -38.5% |
| FY 2024 | $159.52M | +16.0% |
| FY 2023 | $137.54M | +50.5% |
| FY 2022 | $91.39M | +47.1% |
| FY 2021 | $62.12M | +4327.4% |
| FY 2020 | $1.40M | -97.1% |
| FY 2019 | $48.94M | +952.9% |
| FY 2018 | -$5.74M | -257.3% |
| FY 2017 |
Amphastar Pharmaceuticals, Inc. (AMPH) reported net income of $98.09M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Amphastar Pharmaceuticals, Inc.'s net income grew from $18.09M to $98.09M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.65M |
| -62.9% |
| FY 2016 | $9.82M | +452.4% |
| FY 2015 | -$2.79M | +74.0% |
| FY 2014 | -$10.70M | -190.2% |
| FY 2013 | $11.86M | -34.4% |
| FY 2012 | $18.09M | - |